Saturday, July 27, 2024

Healthcare

NurExone Biologics: Promising Future in Regenerative Medicine

NurExone Biologics is developing exosome-based therapies for non-invasive treatment of central nervous system injuries, with their lead product, ExoPTEN, showing significant promise in preclinical...

RenovoRx’s Breakthroughs in Targeted Cancer Treatments

RenovoTAMP™ Technology: Innovative targeted chemotherapy delivery system. Clinical Validation: Supported by recent publications and new studies. Market Potential: Positioned within a projected $220.5 billion cancer therapy...

NurExone Biologic Advances Glaucoma Research with Cutting-Edge Exosome-Based Therapies (TSXV: NRX, OTCQB: NRXBF)

TORONTO and HAIFA, Israel, June 28, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a...

NurExone Biologic Inc. Accelerates Growth with Dr. Yona Geffen’s Expertise (TSXV: NRX, OTCQB: NRXBF)

NurExone Biologic Inc TORONTO and HAIFA, Israel, June 21, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90 is a pioneering...

NurExone’s Game-Changing Moves in Biopharmaceuticals and Exosome Technology (TSXV: NRX, OTCQB: NRXBF, FSE: J90, NRX.V)

NurExone (TSXV: NRX) (Germany: J90)  (the “Company” or “NurExone") is a pioneering biopharmaceutical company developing regenerative medicine therapies. For a quick catch up on NRX, here are...

Popular

Subscribe

spot_imgspot_img